Core Viewpoint - The stock of Yidu Tech (02158) has increased by over 6%, currently trading at 7.12 HKD with a transaction volume of 112 million HKD, following the announcement of a significant project win [1] Group 1: Company Developments - Yidu Tech's subsidiary, Tianjin Happy Life Technology Co., Ltd., has won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd., with a total project value of approximately 55.82 million RMB [1] - At the "First Medical Artificial Intelligence Conference and Health Industry AI Application and Development Exhibition" held in Jinan, Dr. Li Linfeng, Vice President of Technology Innovation and AI Architect at Yidu Tech, presented the "Doctor Copilot" system, which integrates big data and Yidu's domain-specific models to enhance clinical workflows [1] Group 2: Industry Insights - The "AI-Driven Improvement of Medical Quality" forum highlighted the application of Yidu Tech's Doctor Copilot in multiple hospitals, demonstrating its effectiveness in enhancing diagnostic and treatment efficiency, thereby supporting the intelligent and standardized upgrade of clinical practices [1]
港股异动 | 医渡科技(02158)涨超6% AI医疗业务持续推进 近期中标SMR001滴眼液III期临床研究项目